Eli Lilly is addressing the "social duty" of GLP-1 drugs, according to the Readout newsletter.[1] Merck announced the $6.7 billion purchase of Terns Pharmaceuticals, which is developing the promising leukemia treatment TERN-701.[1] The deal values Terns at $53 per share, a 6% premium to Tuesday's closing price.[1] Terns shares have risen sixfold in the past six months on the drug's potential and takeover speculation.[1] For Merck, it is about strengthening the portfolio of oncology drugs before the loss of Keytruda's patent protection.[1] The Bulletin Readout summarizes these and other biotech news.[1]